



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Springer *et al.*

Appl. No.: 09/722,495

Filed: November 28, 2000

For: **Analogs of Human Basic Fibroblast  
Growth Factor Mutated at One or  
More of the Positions Glutamate 89,  
Aspartate 101 or Leucine 137**

Confirmation No.: 5579

Art Unit: 1647

Examiner: Saoud, C. J.

Atty Docket: 1503.0220002/JAG/THN

RECEIVED

AUG 23 2002

TECH CENTER 1600/2900

**Amendment and Reply Under 37 C.F.R § 1.111 and  
Submission of Substitute Sequence Listing Under 37 C.F.R. § 1.825(a)**

Commissioner for Patents  
Washington, DC 20231

Sir:

In reply to the Office Action dated March 21, 2002 (PTO File Wrapper Paper No. 5), Applicants submit the following Amendment and Remarks. This Amendment is provided in the following format:

(A) A clean version of each replacement paragraph/section/claim along with clear instructions for entry;

(B) Starting on a separate page, appropriate remarks and arguments. 37 C.F.R. § 1.111 and MPEP 714; and

(C) Starting on a separate page, a marked-up version entitled: "Version with markings to show changes made."

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper.

However, if additional extensions of time are necessary to prevent abandonment of this

08/23/2002 AOSMANI 00000045 09722495

02 FC:202  
03 FC:203  
01

42.00 OP  
180.00 OP  
140.00 OP